Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Shin Poog Pharmaceutical Co., Ltd.

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of SPC1001 in Patients With Essential Hypertension

Phase 2

Recruiting

Conditions: Hypertension, Essential
Cardiovascular Diseases
Cardiology

Interventions: Drug: SPC 1001 Mid2
Drug: SPC 2003
Drug: SPC 2002
Drug: SPC 2004

First Posted Date: 2025-02-14

Last Posted Date: 2025-02-14

Lead Sponsor: Shin Poong Pharmaceutical Co. Ltd.

Target Recruit Count: 252

Registration Number: NCT06826872

Locations: 🇰🇷
CHA Gangnam Medical Center, CHA University, Seoul, Republic of Korea, Seoul, Korea, Republic of

Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care

Phase 3

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: SP-8203
Drug: Placebo

First Posted Date: 2024-10-28

Last Posted Date: 2025-03-07

Lead Sponsor: Shin Poong Pharmaceutical Co. Ltd.

Target Recruit Count: 852

Registration Number: NCT06660719

Locations: 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷
Ulsan University Hospital, Ulsan, Korea, Republic of

Pivotal Study to Evaluate Efficacy and Safety of SP5M002 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis

Phase 3

Active, not recruiting

Conditions: Osteoarthritis

Interventions: Device: Synovian inj
Device: SP5M002 inj

First Posted Date: 2024-05-03

Last Posted Date: 2024-05-03

Lead Sponsor: Shin Poong Pharmaceutical Co. Ltd.

Target Recruit Count: 297

Registration Number: NCT06399042

Locations: 🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷
Yeungnam University Medical Center, Daegu, Korea, Republic of
🇰🇷
Chonnam National University Bitgoeul Hospital, Gwangju, Korea, Republic of

and more 13 locations

Pivotal Study to Evaluate Efficacy and Safety of SP5M001 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis

Phase 3

Completed

Conditions: Osteoarthritis Thumb

Interventions: Drug: SP5M001 inj
Drug: Synovian inj

First Posted Date: 2024-03-13

Last Posted Date: 2024-03-13

Lead Sponsor: Shin Poong Pharmaceutical Co. Ltd.

Target Recruit Count: 223

Registration Number: NCT06307847

Locations: 🇰🇷
Yeungnam University Medical Center, Daegu, Korea, Republic of
🇰🇷
Cheonam National University Hwasun Hospital, Hwasun, Korea, Republic of
🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of

and more 11 locations

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Ezerosu Tab

Phase 1

Completed

Conditions: Hyperlipidemias

Interventions: Drug: Ezerosu(monolayer tablet)
Drug: Ezerosu(double layer tablet)

First Posted Date: 2024-01-26

Last Posted Date: 2024-01-26

Lead Sponsor: Shin Poong Pharmaceutical Co. Ltd.

Target Recruit Count: 60

Registration Number: NCT06225635

Locations: 🇰🇷
H Plus Yangji Hospital, Seoul, Korea, Republic of

Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension

Phase 2

Completed

Conditions: Hypertension
Essential Hypertension

Interventions: Drug: SPC1001 High
Drug: SPC1001 Mid1
Drug: SPC1001 Mid2
Drug: SPC1001 Low
Drug: SPC3001
Drug: SPC4001
Drug: SPC4002
Drug: Placebo

First Posted Date: 2024-01-19

Last Posted Date: 2024-01-19

Lead Sponsor: Shin Poong Pharmaceutical Co. Ltd.

Target Recruit Count: 253

Registration Number: NCT06212648

Locations: 🇰🇷
CHA Gangnam Medical Center, CHA University, Seoul, Gangnam, Korea, Republic of

Pilot Clinical Trial to Explore Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Pyramax

First Posted Date: 2022-12-01

Last Posted Date: 2022-12-02

Lead Sponsor: Shin Poong Pharmaceutical Co. Ltd.

Target Recruit Count: 20

Registration Number: NCT05633420

Locations: 🇰🇷
Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Inha University Hospital, Incheon, Korea, Republic of

A Phase I Study to Evaluate Safety and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8356

Phase 1

Terminated

Conditions: Atherosclerosis
Ischemic Stroke

Interventions: Drug: SP-8356
Drug: Placebo

First Posted Date: 2022-10-10

Last Posted Date: 2022-10-10

Lead Sponsor: Shin Poong Pharmaceutical Co. Ltd.

Target Recruit Count: 31

Registration Number: NCT05574166

Locations: 🇬🇧
Quotient Sciences, Nottingham, Mere Way Ruddington Fields Ruddington, United Kingdom

The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients (Phase3)

Phase 3

Completed

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: Pyramax

First Posted Date: 2021-10-20

Last Posted Date: 2023-06-18

Lead Sponsor: Shin Poong Pharmaceutical Co. Ltd.

Target Recruit Count: 1807

Registration Number: NCT05084911

Locations: 🇦🇷
Instituto Medico Platense, Buenos Aires, Argentina
🇦🇷
Ciprec - Centro de Investigación Y Prevención Cardiovascular, Caba, Argentina
🇦🇷
Hospital de Agudos "Dr. Ignacio Pirovano", Caba, Argentina

and more 63 locations

Anti-adhesive Effect and Safety of MEDICURTAIN Applied to Undergoing Thyroid Surgery (Pivotal Study)

Not Applicable

Completed

Conditions: Tissue Adhesion, Surgery-Induced

Interventions: Device: GUARDIX-SG®
Device: Medicurtain®

First Posted Date: 2021-09-27

Last Posted Date: 2021-09-27

Lead Sponsor: Shin Poong Pharmaceutical Co. Ltd.

Target Recruit Count: 170

Registration Number: NCT05058027

Locations: 🇰🇷
Ewha Womans University Mokdong Hospital, Seoul, Gangnam-gu, Eonju-ro, 211, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy